Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


2nd World Heart Congress

Tokyo, Japan

Martina Cebova

Center of Experimental Medicine Slovak Academy of Sciences, Slovak Republic

Title: Protective effect of anti-HMGB1 protein in experimental myocardial infarction


Biography: Martina Cebova


High mobility group box 1 (HMGB1) is a non-histone chromosomal protein associated with various pathological conditions such as cardiovascular disease, cancer and ischemia/reperfusion injury. The aim of the study was to evaluate the effects of HMGB1 protein on biochemical and morphological parameters after experimental myocardial infarction (MI). 12-week-old Wistar-Kyoto (WKY) male rats used for the study were divided into following groups: shame operated WKY without MI, WKY with MI, WKY + IM+ anti-HMGB1 protein. In vivo model of experimental MI was induced by ligation of the left descending coronary artery and lasted 20 min. Before reperfusion anti HMGB1 protein was administrated I.V. Animals survived 7 days after MI. NOS activity was determined by conversion of 3[H] Arginine to 3[H] Citrulline in the aorta and ischemic, border and non-ischemic region of the heart. NFҡB expression was determined by Western blot. For morphological parameters, the hearts were processed by TTC-staining procedure. Cytokine levels were determined in the plasma. Concentration of CD was measured spectrophotometrically. Anti-HMGB1 protein increased NOS activity in both ischemic and border part of the heart, as well as in the aorta. It significantly decreased NFҡB expression in MI part of the heart, TNF-alpha and IL-6 level in plasma. Simultaneously, anti-HMGB1 protein decreased MI part as well as border region of the heart. Considering the results, HMGB1 protein is a promising molecule for reduction the negative effects of the myocardium infarction, as well as a promising agent for the treatment of cardiovascular diseases.